Navigation Links
Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders
Date:12/15/2010

INDIANAPOLIS, Dec. 15, 2010 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today issued the following statement from John Lechleiter, Ph.D., chairman, president, and chief executive officer about his meeting today with President Obama and other business leaders regarding economic growth, job creation, American innovation and competiveness:

"It's an honor to represent Lilly and the biopharmaceutical industry and take part in this very important dialogue today with the President and other leaders across many industries. Fostering an environment that encourages innovation is fundamental to American job growth. For instance, our industry has a long history of addressing critical medical needs through innovative research and discovery. We need policies that support and help sustain American innovation.

"We also believe that local innovation hubs – such as the life science hub we have in Indiana -- can serve as the fuel for national prosperity. From 2001 to 2007, employment in Indiana life sciences industries grew at more than twice the national rate. The annual wage of a typical life sciences job in Indiana is more than double the average wage in the state. And the total value of Indiana life sciences exports more than doubled between 2002 and 2007. I look forward to discussing how Indiana's success story can be used as a model for job growth.

"Ultimately, with public policies that provide the right environment, I'm convinced America can out-innovate anyone and create a new wave of good jobs here at home."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Suspends Phase III Trial in Metastatic Melanoma
2. Lilly Declares First-Quarter 2011 Dividend
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lilly Surpasses United Way 2010 Campaign Goal
5. Breast Cancer Message Barred in Eli Lillys Hometown
6. Eli Lilly and Company to Open a Diabetes-Focused Research Center in China
7. Lilly USA, LLC Wins Award in 2010 National Health Information Awards Program
8. Lilly CEO: Are We Getting Our Moneys Worth from Medical Innovation?
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Eli Lilly and Company and PPD, Inc., Honored for Building Strong Clinical Research Site Partnerships at the Site Solutions Summit Annual Meeting
11. Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CITY, Calif. , March 28, 2017 /PRNewswire/ ... company focused on the development and commercialization of ... pain, announced that the European Medicines Agency (EMA) ... sublingual tablet, 30 mcg) Marketing Authorisation Application (MAA) ... of the MAA is underway. The MAA for ...
(Date:3/28/2017)... Mass. , March 28, 2017 ... company developing innovative therapeutics that address significant unmet ... a patent from the Japan Patent Office (JPO) ... connective tissue growth factor (CTGF) for the treatment ... limited to skin fibrosis and proliferative retinopathy (Japanese ...
(Date:3/28/2017)... , March 28, 2017 The ... reach USD 8.0 billion by 2025, according to a ... incidence of infectious diseases and cancer is expected to ... disease diagnosis over the coming years. In addition, higher ... autologous and allogenic stem cell therapy, due to adverse ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution for Truth has organized ... protect parental rights and civil liberties, and to restore transparency within government agencies ... coincides with a press conference taking place Friday morning calling on President Trump ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... 2017 , ... Z-Medica, LLC, a leading developer and marketer ... will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up to 1,000 schools ... by the American College of Surgeons, U.S. Department of Defense, Department of Homeland ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... instruments are critical to ensuring high-quality results and maintaining GMP and USP compliance. ... Laboratory Instruments in accordance with GMP requirements " these requirements are explained. ...
(Date:3/28/2017)... ... 2017 , ... With less than 10,000 dermatologists in the United States and ... limited while the desire to conquer breakouts and eliminate skincare stress is widespread. ... online, today released its inaugural survey on the State of Acne in America. ...
Breaking Medicine News(10 mins):